Insulet resumed with a Buy at Stifel

Stifel resumed coverage of Insulet (PODD) with a Buy rating and $370 price target The firm expects the company’s current momentum to continue, creating upward revisions to its guidance. Stifel’s survey work suggests the type 2 insulin-intensive opportunity “has legs” for pump providers and that the patch is the preferred form factor, the analyst tells investors in a research note.